vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and Legacy Education Inc. (LGCY). Click either name above to swap in a different company.

Legacy Education Inc. is the larger business by last-quarter revenue ($19.2M vs $13.5M, roughly 1.4× Assertio Holdings, Inc.). On growth, Legacy Education Inc. posted the faster year-over-year revenue change (40.7% vs -57.9%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Legacy Education Inc. is a professional educational service provider focused on financial literacy, real estate investment, entrepreneurship, and personal wealth management training programs. It mainly serves individual learners across North America, Europe and select Asia-Pacific markets, offering both in-person workshops and online digital courses to help users build practical financial and business skills.

ASRT vs LGCY — Head-to-Head

Bigger by revenue
LGCY
LGCY
1.4× larger
LGCY
$19.2M
$13.5M
ASRT
Growing faster (revenue YoY)
LGCY
LGCY
+98.6% gap
LGCY
40.7%
-57.9%
ASRT

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ASRT
ASRT
LGCY
LGCY
Revenue
$13.5M
$19.2M
Net Profit
$2.0M
Gross Margin
Operating Margin
-86.7%
13.3%
Net Margin
10.6%
Revenue YoY
-57.9%
40.7%
Net Profit YoY
46.0%
EPS (diluted)
$-4.54
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
LGCY
LGCY
Q4 25
$13.5M
$19.2M
Q3 25
$49.5M
$19.4M
Q2 25
$29.2M
$18.0M
Q1 25
$26.5M
$18.6M
Q4 24
$32.2M
$13.6M
Q3 24
$29.2M
$14.0M
Q2 24
$31.1M
Q1 24
$32.4M
Net Profit
ASRT
ASRT
LGCY
LGCY
Q4 25
$2.0M
Q3 25
$11.4M
$2.2M
Q2 25
$-16.4M
$1.2M
Q1 25
$-13.5M
$2.8M
Q4 24
$1.4M
Q3 24
$-2.9M
$2.1M
Q2 24
$-3.7M
Q1 24
$-4.5M
Operating Margin
ASRT
ASRT
LGCY
LGCY
Q4 25
-86.7%
13.3%
Q3 25
23.2%
13.9%
Q2 25
-27.5%
11.1%
Q1 25
-50.0%
19.7%
Q4 24
-41.9%
12.2%
Q3 24
-10.4%
19.1%
Q2 24
-11.6%
Q1 24
-13.4%
Net Margin
ASRT
ASRT
LGCY
LGCY
Q4 25
10.6%
Q3 25
23.1%
11.3%
Q2 25
-56.0%
6.8%
Q1 25
-51.1%
15.2%
Q4 24
10.3%
Q3 24
-10.0%
14.9%
Q2 24
-11.8%
Q1 24
-13.9%
EPS (diluted)
ASRT
ASRT
LGCY
LGCY
Q4 25
$-4.54
$0.15
Q3 25
$0.11
$0.16
Q2 25
$-0.17
$0.07
Q1 25
$-0.14
$0.21
Q4 24
$-3.28
$0.10
Q3 24
$-0.03
$0.21
Q2 24
$-0.04
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
LGCY
LGCY
Cash + ST InvestmentsLiquidity on hand
$63.4M
$21.1M
Total DebtLower is stronger
$660.3K
Stockholders' EquityBook value
$94.0M
$46.1M
Total Assets
$267.0M
$73.1M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
LGCY
LGCY
Q4 25
$63.4M
$21.1M
Q3 25
$93.4M
$20.6M
Q2 25
$98.2M
$20.3M
Q1 25
$87.3M
$17.3M
Q4 24
$100.1M
$16.9M
Q3 24
$88.6M
$21.5M
Q2 24
$88.4M
Q1 24
$80.7M
Total Debt
ASRT
ASRT
LGCY
LGCY
Q4 25
$660.3K
Q3 25
$776.9K
Q2 25
$1.4M
Q1 25
$1.0M
Q4 24
$1.1M
Q3 24
$758.2K
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
LGCY
LGCY
Q4 25
$94.0M
$46.1M
Q3 25
$105.8M
$43.7M
Q2 25
$93.3M
$41.0M
Q1 25
$108.5M
$39.3M
Q4 24
$121.1M
$36.4M
Q3 24
$130.5M
$32.6M
Q2 24
$132.2M
Q1 24
$134.5M
Total Assets
ASRT
ASRT
LGCY
LGCY
Q4 25
$267.0M
$73.1M
Q3 25
$319.8M
$72.1M
Q2 25
$273.8M
$69.2M
Q1 25
$286.4M
$67.1M
Q4 24
$284.7M
$62.1M
Q3 24
$276.0M
$50.6M
Q2 24
$279.4M
Q1 24
$282.0M
Debt / Equity
ASRT
ASRT
LGCY
LGCY
Q4 25
0.01×
Q3 25
0.02×
Q2 25
0.03×
Q1 25
0.03×
Q4 24
0.03×
Q3 24
0.02×
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
LGCY
LGCY
Operating Cash FlowLast quarter
$-30.0M
$1.1M
Free Cash FlowOCF − Capex
$512.7K
FCF MarginFCF / Revenue
2.7%
Capex IntensityCapex / Revenue
2.8%
Cash ConversionOCF / Net Profit
0.52×
TTM Free Cash FlowTrailing 4 quarters
$4.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
LGCY
LGCY
Q4 25
$-30.0M
$1.1M
Q3 25
$-4.8M
$1.1M
Q2 25
$19.1M
$3.0M
Q1 25
$-12.5M
$918.7K
Q4 24
$11.5M
$659.0K
Q3 24
$-35.0K
$3.2M
Q2 24
$7.4M
Q1 24
$7.5M
Free Cash Flow
ASRT
ASRT
LGCY
LGCY
Q4 25
$512.7K
Q3 25
$809.7K
Q2 25
$2.9M
Q1 25
$596.6K
Q4 24
$466.8K
Q3 24
$2.9M
Q2 24
Q1 24
FCF Margin
ASRT
ASRT
LGCY
LGCY
Q4 25
2.7%
Q3 25
4.2%
Q2 25
16.2%
Q1 25
3.2%
Q4 24
3.4%
Q3 24
21.1%
Q2 24
Q1 24
Capex Intensity
ASRT
ASRT
LGCY
LGCY
Q4 25
2.8%
Q3 25
1.3%
Q2 25
0.5%
Q1 25
1.7%
Q4 24
1.4%
Q3 24
0.0%
1.7%
Q2 24
Q1 24
Cash Conversion
ASRT
ASRT
LGCY
LGCY
Q4 25
0.52×
Q3 25
-0.42×
0.48×
Q2 25
2.45×
Q1 25
0.33×
Q4 24
0.47×
Q3 24
1.52×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

LGCY
LGCY

Segment breakdown not available.

Related Comparisons